Overview of the Global Systemic Lupus Erythematosus Pipeline and the Next Three Potential Product Launches
Overview of the Global Systemic Lupus Erythematosus Pipeline and the Next Three Potential Product Launches
RELEASE DATE
22-Feb-2013
22-Feb-2013
REGION
Global
Global
Research Code: 9837-00-55-00-00
SKU: LS00066-GL-MR_16907
$1,500.00
In stock
SKU
LS00066-GL-MR_16907
Description
This research service provides an introduction to systemic lupus erythematosus (SLE), disease classification and diagnosis. Research in this report overviews the current status of SLE pipeline candidates with a focus on current Phase 3 candidates, detailed timelines with accrual rate and approval estimates for U.S. and European markets, ranking of the approval likeliness for current Phase 3 candidates, rationale for pivotal program design, Phase 2 data review, and KOL commentary. A pipeline assessment is provided for all active SLE candidates in development.
Table of Contents
Executive Summary
Methodology and Scope
Introduction
Competitive Landscape
Timeline Transparency
SLE Drug Trial Results
Product Dashboards
The Future of Treatment Decisions
Appendix
The Frost & Sullivan Story
Related Research
Popular Topics
Top 10 Growth Opportunities for 2023
residential energy storage market
This issue of Vital Signs discusses the change in 2015 Mammogram Guidelines, NeoGenomics' acquistion of Clarient from GE, and Tute Genomics' acquisition of Knome.
No Index | Yes |
---|---|
Podcast | No |
WIP Number | 9837-00-55-00-00 |
Is Prebook | No |